Santen Pharmaceutical (OTCMKTS:SNPHY) Reaches New 12-Month High – Still a Buy?

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) shares reached a new 52-week high during mid-day trading on Monday . The company traded as high as $12.22 and last traded at $12.22, with a volume of 861 shares. The stock had previously closed at $11.4850.

Santen Pharmaceutical Stock Performance

The company’s 50 day moving average price is $10.97 and its 200-day moving average price is $10.62. The stock has a market cap of $3.93 billion and a P/E ratio of 0.10.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.